Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17

Author: Benzinga Newsdesk | April 18, 2024 09:00am

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Perform and lowers the price target from $25 to $17.

Posted In: SAGE